Targeted Antibacterial Antitumor Agent

Relapse-free survival >700 days

A single agent integrates antibacterial and multimodal therapy, restoring immune surveillance and establishing long-term immune memory

Wang, Yuanlin · Han, Yaqian · Yang, Chenhui · Wang, Zhaotong · Sun, Ye · Hu, Ying · Besenbacher, Flemming · Chen, Chunying · Yu, Miao

Nature Communications 2024

Specifications

Relapse-free survival
{'zh': '', 'en': '>700'} days

Advantages

Simultaneous bacterial killing and multimodal antitumor therapy (Ag+ release, Fenton-like reaction, photothermal conversion)

Free of immune-stimulating drugs, restores antitumor immune surveillance

Secondary inoculation and distal tumor analysis confirm lasting immunological memory and systemic immune responses